Table 2.
Some examples of nanomedicines on the market
| Name | Nanomedicine | Status | Indications |
|---|---|---|---|
| Abraxane | Albumin-bound paclitaxel nanoparticles | Approved in 2005 | Metastatic breast and pancreatic cancer |
| Ambisome | Liposomal amphotericin B | Approved in 1997 | Fungal infections |
| Daunoxome | Liposomal daunorubicin | Approved in 1996 | Kaposi's sarcoma |
| DepoDur | Liposomal morphine | Approved in 2004 | Post-surgical pain relief |
| Doxil | Liposomal doxorubicin | Approved in 1995 | Ovarian cancer, Kaposi's Sarcoma |
| Genexol-PM | Polymeric micelles with paclitaxel | Available in Asian countries | Breast and lung cancers |
| Myocet | Liposomal doxorubicin (no PEGylation) | Available in Canada and Europe | Metastatic breast cancer |
| Neulasta | PEG-granulocyte colony-stimulating factor(PEG-CSF) | Approved in 2002 | Febrile neutropenia |
| Oncaspar | PEG-L-asparaginase | Approved in 1994 | Lymphocytic leukemia, Non-Hodgkin's lymphoma |
| PEGASYS | PEG-interferon α2a | Approved in 2002 | Hepatitis C |
| PEGIntron | PEG-interferon α2b | Approved in 2001 | Hepatitis C |
| Visudyne | Liposomal verteporfin | Approved in 2000 | Age-related macular degeneration |